HIV drug resistance , Users Manual
December 2017
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01
Developed in collaboration with the International Council of AIDS Service Organizations (ICASO)
Strengthening Community responses to HIv Treatment and Prevention
A toolkit to equip young people with the skills to become powerful advocates for Youth Sexual Reproductive Health and Rights (YSRH&R)
Accessed: 17.11.2019
Vision 2030
Accessed: 17.11.2019
From choice, a world of possibilities
Want to change the world? Here's how...
"i asked: 'Why doesn't somebody do something?' Then I realized I was somebody"